Antitumour and immune-adjuvant activities of protein-tyrosine kinase inhibitors

Trends in Molecular Medicine

Volumn 16, Issue 4, 2010, Pages 184-192

  Seliger, Barbara ^a   Massa, Chiara ^a   Rini, Brian ^b   Ko, Jennifer ^c   Finke, Jim ^b  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b Taussig Cancer Institute   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CEDIRANIB; IMATINIB; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB;

ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DENDRITIC CELL; DRUG EFFECT; DRUG TARGETING; HUMAN; HYPERTENSION; IMMUNOMODULATION; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; MONOCYTE; NATURAL KILLER CELL; NONHUMAN; PROGRESSION FREE SURVIVAL; REGULATORY T LYMPHOCYTE; REVIEW; TREATMENT RESPONSE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DENDRITIC CELLS; HUMANS; IMMUNOTHERAPY; MICE; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN KINASE INHIBITORS; T-LYMPHOCYTES, REGULATORY;

EID: 77950519079     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmed.2010.02.001     Document Type: Review

References (65)

1. Cohen M.H., et al. Report from the FDA: approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin. Cancer Res. 8 (2002) 935-942
2. ÓBrien S., et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med. 348 (2003) 994-1004
3. Dagher R., et al. Report from the FDA: approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin. Cancer Res. 8 (2002) 3034-3038
4. Adnane L., et al. Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Methods Enzymol. 407 (2006) 597-612
5. Ratain M.J., et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 24 (2006) 2505-2512
6. Escudier B., et al. Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma. Clin. Cancer Res. 13 (2007) 1801-1809
7. Escudier B., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 356 (2007) 125-134
8. Abou-Alfa G.K., et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J. Clin. Oncol. 24 (2006) 4293-4300
9. Llovet J.M., et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359 (2008) 378-390
10. Motzer R.J., et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA. 295 (2006) 2516-2524
11. Motzer R.J., et al. Sunitinib versus interferon alpha in metastatic renal-cell carcinoma. N. Engl. J. Med. 356 (2007) 115-124
12. Demetri G.D., et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib a randomized controlled trial. Lancet 368 (2006) 1329-1338
13. Liu L., et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res. 66 (2006) 11851-11858
14. Xin H., et al. Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. Cancer Res. 69 (2009) 2506-2513
15. Hillman G.G., et al. Dynamic contrast-enhanced magnetic resonance imaging of vascular changes induced by sunitinib in papillary renal cell carcinoma xenograft tumors. Neoplasia 11 (2009) 910-920
16. Van der Veldt, A.A. et al. (2010) Reduction in skin microvascular density and changes in vessel morphology in patients treated with sunitinib. Anticancer drugs DOI: 10.10197/CAD.0b013e3283359c79 (http://journals.lww.com/anti-cancerdrugs/pages/default.aspx)
17. Heckman C.A., et al. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis. Cancer Res. 68 (2008) 4754-4762
18. Padera T.P., et al. Differential response of primary tumor versus lymphatic metastasis to VEGFR-2 and VEGFR-3 kinase inhibitors cediranib and vandetanib. Mol. Cancer Ther. 7 (2008) 2272-2279
19. Quintás-Cardama A., et al. Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia. Cancer Control: Journal of the Moffitt Cancer Center 16 2 (2009) 122-131
20. Zhang W.W., et al. Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance. J. Clin. Oncol. 27 (2009) 3642-3649
21. Perez-Gracia J.L., et al. Identification of TNF-alpha and MMP-9 as potential baseline predictive serum markers of sunitinib activity in patients with renal cell carcinoma using a human cytokine array. Br. J. Cancer 101 (2009) 1876-1883
22. Hirsch F.R., et al. Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer. Oncogene 28 Suppl 1 (2009) S32-37
23. McWeeney S.K., et al. A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic phase chronic myeloid leukemia patients treated with imatinib. Blood 115 (2009) 315-325
24. Dahabreh I.J., et al. Somatic EGFR mutation and gene copy gain as predictive biomarkers for response to tyrosine kinase inhibitors in non-small cell lung cancer. Clin. Cancer Res. 16 (2010) 291-303
25. Finke J.H., et al. Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin. Cancer Res. 14 (2008) 6674-6682
26. Ozao-Choy J., et al. The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res. 69 (2009) 2514-2522
27. Gouttefangeas C., et al. Immunotherapy of renal cell carcinoma. Cancer Immunol Immunother. 56 (2007) 117-128
28. Hoeltl L., et al. Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells. J. Urol. 161 (1999) 777-782
29. Su Z., et al. Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. Cancer Res. 63 (2003) 2127-2133
30. Bleumer I., et al. Preliminary analysis of patients with progressive renal cell carcinoma vaccinated with CA9-peptide-pulsed mature dendritic cells. J. Immunother. 30 (2007) 116-122
31. Berntsen A., et al. Therapeutic dendritic cell vaccination of patients with metastatic renal cell carcinoma: a clinical phase 1/2 trial. J. Immunother. 31 (2008) 771-780
32. Asemissen A.M., and Brossart P. Vaccination strategies in patients with renal cell carcinoma. Cancer Immunol Immunother. 58 (2009) 1169-1174
33. Rosenberg S.A., et al. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat. Rev. Cancer 8 (2008) 299-308
34. Blay J.Y., et al. Role of interleukin-6 in the paraneoplastic inflammatory syndrome associated with renal-cell carcinoma. Int. J. Cancer. 72 (1997) 424-430
35. Choudeiri T.K., et al. Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer 110 (2007) 543-550
36. Young M.R., and Lathers D.M. Myeloid progenitor cells mediate immune suppression in patients with head and neck cancers. Int. J. Immunopharmacol. 21 (1999) 241-252
37. Almand B., et al. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J. Immunol. 166 (2001) 678-689
38. Pan P.Y., et al. Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function. Blood 111 (2008) 219-228
39. Bronte V., et al. Tumor-induced immune dysfunctions caused by myeloid suppressor cells. J. Immunother. 24 (2001) 431-446
40. Ko J.S., et al. Myeloid-derived suppressor cells: a novel therapeutic target. Curr. Oncol. Rep. 11 (2009) 87-93
41. Gabrilovich D., et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat. Med. 2 (1996) 1096-1103
42. Gabrilovich D., et al. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 92 (1998) 4150-4166
43. Alfaro C., et al. Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes. Br. J. Cancer 100 (2009) 1111-1119
44. Mohty M., et al. Imatinib: the narrow line between immune tolerance and activation. Trends Mol. Med. 11 (2005) 397-402
45. Seggewiss R., et al. Immunomodulatory effects of imatinib and second-generation tyrosine kinase inhibitors on T cells and dendritic cells: an update. Cytotherapy 10 (2008) 633-641
46. Hipp M.M., et al. Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses. Blood 111 (2008) 5610-5620
47. + dendritic cell frequency predicts progression-free survival. Clin. Cancer Res. 14 (2008) 5884-5892
48. Ko J.S., et al. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin. Cancer Res. 15 (2009) 2148-2157
49. Molhoek K.R., et al. Apoptosis of CD4(+)CD25(high) T cells in response to Sirolimus requires activation of T cell receptor and is modulated by IL-2. Cancer Immunol Immunother. 58 (2009) 867-876
50. Hilger R.A., et al. Correlation of ERK-phosphorylation and toxicities in patients treated with the Raf kinase inhibitor BAY 43-9006. Int. J. Clin. Pharmacol. Ther. 42 (2004) 648-649
51. Zhao W., et al. Sorafenib inhibits activation of human peripheral blood T cells by targeting LCK phosphorylation. Leukemia. 22 (2008) 1226-1233
52. Houben R., et al. MAPK-independent impairment of T-cell responses by the multikinase inhibitor sorafenib. Mol. Cancer Ther. 8 (2009) 433-440
53. Boissel N., et al. Imatinib mesylate minimally affects bcr-abl+ and normal monocyte-derived dendritic cells but strongly inhibits T cell expansion despite reciprocal dendritic cell-T cell activation. J. Leukoc. Biol. 79 (2006) 747-756
54. Mumprecht S., et al. Imatinib mesylate selectively impairs expansion of memory cytotoxic T cells without affecting the control of primary viral infections. Blood 108 (2006) 3406-3413
55. Sinai P., et al. Imatinib mesylate inhibits antigen-specific memory CD8 T cell responses in vivo. J. Immunol. 178 (2007) 2028-2037
56. Pinilla-Ibarz J., et al. The biological basis for immunotherapy in patients with chronic myelogenous leukemia. Cancer Control 16 (2009) 141-152
57. Rojas J.M. Clinical evaluation of BCR-ABL peptide immunisation in chronic myeloid leukaemia: results of the EPIC study. Leukemia. 21 (2007) 2287-2295
58. Wang H., et al. Imatinib mesylate (STI-571) enhances antigen-presenting cell function and overcomes tumor-induced CD4+ T-cell tolerance. Blood 105 (2005) 1135-1143
59. Mohty M., et al. Imatinib and plasmacytoid dendritic cell function in patients with chronic myeloid leukemia. Blood 103 (2004) 4666-4668
60. Borg C., et al. Novel mode of action of c-Kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. J. Clin. Invest. 114 (2004) 379-388
61. Bellone M., et al. Vascular targeting, chemotherapy and active immunotherapy: teaming up to attack cancer. Trends Immunol. 29 (2008) 235-241
62. Griffioen A.W. Anti-angiogenesis: making the tumor vulnerable to the immune system. Cancer Immunol Immunother. 57 (2008) 1553-1558
63. Fraser C.K., et al. Dasatinib inhibits recombinant viral antigen-specific murine CD4+ and CD8+ T-cell responses and NK-cell cytolytic activity in vitro and in vivo. Exp. Hematol. 37 (2009) 256-265
64. Louvet C., et al. Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 18895-18900
65. Himmelsbach K., et al. New aspects of an anti-tumor drug: sorafenib efficiently inhibits HCV replication. Gut. 58 (2009) 1644-1653